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Abstract 
Cobalt-60 (Co-60) is a relatively new source for the application of high-dose rate (HDR) 
brachytherapy. Radiation dose to the rectum is often a limiting factor in achieving the full 
prescribed dose to the target during brachytherapy of cervical cancer. The aim of this study 
was to measure radiation doses to the rectum in-vivo during HDR Co-60 brachytherapy. A 
total of eleven HDR brachytherapy treatments of cervical cancer were recruited in this study. 
A series of diodes incorporated in a rectal probe was inserted into the patient's rectum during 
each brachytherapy procedure. Real-time measured rectal doses were compared to calculated 
doses by the treatment planning system (TPS). The differences between calculated and 
measured dose ranged from 8.5% to 41.2%. This corresponds to absolute dose differences 
ranging from 0.3 Gy to 1.5 Gy. A linear relationship was observed between calculated and 
measured doses with linear regression R2 value of 0.88, indicating close association between 
the measured and calculated doses. In general, absorbed doses for the rectum as calculated by 
TPS were observed to be higher than the doses measured using the diode probe. In-vivo 
dosimetry is an important quality assurance method for HDR brachytherapy of cervical 
cancer. It provides information that can contribute to the reduction of errors and discrepancies 
in dose delivery. Our study has shown that in-vivo dosimetry is feasible and can be 
performed to estimate the dose to the rectum during HDR brachytherapy using Co-60. 
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